Kintor PharmaceuticalKNTPF 20 PB Ratio is 6.22 as of Jun. 29, 2026, which is 157% above its 10-year median of 2.42. GuruFocus rates KNTPF with a GF Score™ of 20/100. The stock has 3 warning signs investors should review. Among 1,232 Biotechnology companies, Kintor Pharmaceutical ranks worse than 68.34% on this metric.
The historical rank and industry rank for Kintor Pharmaceutical's PB Ratio or its related term are showing as below:
KNTPF'
s PB Ratio Range Over the Past 10 Years
Min: 0.16 Med: 2.42 Max: 101.74
Current: 4.3
During the past 8 years, Kintor Pharmaceutical's highest PB Ratio was 101.74. The lowest was 0.16. And the median was 2.42.
KNTPF's PB Ratio is ranked worse than 68.34% of 1232
companies
in the Biotechnology industry
Industry Median: 2.835
vs KNTPF: 4.30
During the past 12 months, Kintor Pharmaceutical's average Book Value Per Share Growth Rate was -42.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -51.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -42.00% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Kintor Pharmaceutical was 89.00% per year. The lowest was -51.30% per year. And the median was -37.80% per year.
Back to Basics: PB Ratio
Kintor Pharmaceutical (OTCPK:KNTPF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Kintor Pharmaceutical's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kintor Pharmaceutical PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's PB Ratio distribution charts can be found below:
* The bar in red indicates where Kintor Pharmaceutical's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Kintor Pharmaceutical (KNTPF) has a PB Ratio of 6.22 as of Jun. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Kintor Pharmaceutical and its competitors. This is 157% above median its historical median of 2.42. Over the past decade, Kintor Pharmaceutical's PB Ratio has ranged from 0.16 to 101.74. According to the industry distribution chart, Kintor Pharmaceutical ranks #842 out of 1232 companies in the Biotechnology industry, placing it in the top 68.3%.
Is Kintor Pharmaceutical's PB Ratio too high?
Kintor Pharmaceutical's current PB Ratio of 6.22 is 157% above median its 10-year median of 2.42. Over the past 10 years, this metric has ranged from a low of 0.16 to a high of 101.74. The Biotechnology industry median PB Ratio is 2.84. Kintor Pharmaceutical's value of 6.22 is 119.4% above this industry median. Based on the distribution chart, Kintor Pharmaceutical ranks #842 out of 1232 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Kintor Pharmaceutical has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Kintor Pharmaceutical's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kintor Pharmaceutical ranks #842 out of 1232 companies for PB Ratio. This places Kintor Pharmaceutical in the lower half of its industry. The industry median PB Ratio is 2.84. Kintor Pharmaceutical's value of 6.22 is 119.4% above this benchmark. Historically, Kintor Pharmaceutical's own PB Ratio has ranged from 0.16 to 101.74 over the past decade. While the company's 10-year median is 2.42 vs. the industry median of 2.84, Kintor Pharmaceutical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.84, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kintor Pharmaceutical's current PB Ratio of 6.22 is 119.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Kintor Pharmaceutical and its competitors. For the Biotechnology industry, the median PB Ratio is 2.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kintor Pharmaceutical's current PB Ratio is 6.22, which is 157% above median its own 10-year median of 2.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kintor Pharmaceutical stock overvalued right now?
Kintor Pharmaceutical (KNTPF) has a current PB Ratio of 6.22. The current PB Ratio is 6.22, which is 157% above median its 10-year median of 2.42 and 119.4% above the Biotechnology industry median of 2.84. Kintor Pharmaceutical's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Kintor Pharmaceutical (KNTPF), the current PB Ratio is 6.22 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China, focusing on developing therapeutic drugs for unmet medical needs. Its pipelines cover indications of dermatology, such as AGA and acne vulgaris, and indications of tumors, catering to the unmet medical needs of patients and cosmetics consumers globally. The Group's cosmetic product types include anti-hair loss, acne treatment, and skin whitening products. Kintor's pipeline consists of various drug candidates such as KX-826, AR-PROTAC Compound (GT20029), GT1708F (Hedgehog/SMO Inhibitor), GT0486, and ALK-1 Antibody (GT90001). It has only one reportable operating segment, which is engaged in the research and development of medicine products and extends to functional cosmetics and raw materials.
20GF Score
Get the complete analysis for KNTPF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNTPF has been successfully added to your 
